Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.67 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 4/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250514 | 0.91 | PIK3CG (0.63) | PIK3CGPIK3CAPIK3CBGSK3BCDK2 | |
| SCHEMBL3255150 | 0.88 | PIK3CG (0.59) | PIK3CGPIK3CAPIK3CBPRKCAGSK3B | |
| SCHEMBL3249570 | 0.85 | JAK2 (0.54) | PIK3CGPIK3CAPIK3CBPRKCAGSK3B | |
| SCHEMBL3255217 | 0.85 | PIK3CA (0.58) | PIK3CGPIK3CAPIK3CBGSK3BCDK2 | |
| SCHEMBL3252211 | 0.83 | CDK2 (0.73) | PIK3CGPIK3CAPIK3CBPRKCACDK2 | |
| SCHEMBL3257741 | 0.83 | PIK3CG (0.56) | PIK3CGPIK3CAPIK3CBPRKCAGSK3B | |
| SCHEMBL3253915 | 0.83 | PRKCA (0.47) | PIK3CGPIK3CAPIK3CBPRKCAEGFR | |
| SCHEMBL3247848 | 0.82 | AIMP2 (0.58) | PIK3CGPIK3CAPIK3CBPRKCAGSK3B | |
| SCHEMBL27553674 | 0.81 | PIK3CG (0.51) | PIK3CGPIK3CAPIK3CBPRKCAGSK3B | |
| SCHEMBL3252685 | 0.81 | FLT3 (0.62) | GSK3BCDK2CDK4JAK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521749-B8 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-22 | — | — | EP | claimed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | claimed |
| EP-1521749-A1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | Novartis AG (CH) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005282-A1 | PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | claimed |
| EP-1521749-B8 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-1521749-B1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | disclosed |
| EP-1521749-A1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | Novartis AG (CH) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005282-A1 | PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | MKI67, CCNI, PAH | PIK3CG 330/4885PIK3CA 76/4885PIK3CB 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.